FDA 483 - Serum Institute of India Pvt. Ltd. - July 02, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Serum Institute of India Pvt. Limited Manjari Site in Pune, India, revealed significant deficiencies in vaccine manufacturing processes. Observations included inadequate requalification of equipment for COVID vaccine filling, insufficient data to support cleaning processes between different vaccine products, and an incomplete validation study. The firm also lacked data in qualification reports for reference standards and failed to fully investigate critical defects.
ID · efcd0153-0986-40dd-9ac6-c0b4618419b8